Sterling Capital Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.54M Sell
26,347
-39,687
-60% -$2.34M 0.03% 371
2026
Q2
$3.7M Buy
66,034
+46,519
+238% +$2.42M 0.06% 238
2026
Q1
$936K Sell
19,515
-13,876
-42% -$608K 0.02% 530
2025
Q4
$1.29M Sell
33,391
-3,554
-10% -$136K 0.02% 558
2025
Q3
$1.3M Sell
36,945
-2,396
-6% -$86.7K 0.02% 551
2025
Q2
$1.42M Sell
39,341
-21,325
-35% -$707K 0.02% 510
2025
Q1
$1.89M Buy
60,666
+26,071
+75% +$826K 0.03% 376
2024
Q4
$883K Buy
34,595
+8,071
+30% +$214K 0.01% 672
2024
Q3
$750K Buy
+26,524
New +$735K 0.01% 682

Other funds holding RPRX

Sterling Capital Management's RPRX Position: Q3 2026 in Review

Sterling Capital Management reduced its Royalty Pharma (RPRX) stake by 60% in Q3 2026, selling an estimated $2.34M and leaving 26,347 shares worth $1.54M. The position accounts for 0.03% of the portfolio, ranked #371.

Sterling Capital Management first reported a position in RPRX in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.7M in Q2 2026. 705 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Sterling Capital Management held 26,347 shares of Royalty Pharma worth $1.54M as of Q3 2026.
  • Sterling Capital Management sold 39,687 Royalty Pharma shares in Q3 2026, an estimated $2.34M.
  • Royalty Pharma made up 0.03% of Sterling Capital Management's portfolio in Q3 2026, its #371 holding.
  • Sterling Capital Management first reported a position in Royalty Pharma in Q3 2024 and has held it in 9 quarters since.
  • Sterling Capital Management's Royalty Pharma position peaked at $3.7M in Q2 2026.
  • 705 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.